Trial Profile
A phase II study of Iressa and vinorelbine/gemcitabine in chemo-naive elderly patients with advanced non-small-cell lung cancer screened for EGFR mutation status
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Gemcitabine; Vinorelbine
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IVAN
- 30 Sep 2018 Status changed from active, no longer recruiting to completed.
- 21 May 2012 Results published in the BMC Cancer Journal.
- 05 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.